• LAST PRICE
    11.8200
  • TODAY'S CHANGE (%)
    Trending Down-0.1800 (-1.5000%)
  • Bid / Lots
    11.0500/ 3
  • Ask / Lots
    12.4200/ 1
  • Open / Previous Close
    11.9300 / 12.0000
  • Day Range
    Low 11.7100
    High 11.9400
  • 52 Week Range
    Low 7.1500
    High 13.7700
  • Volume
    134,255
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 12
TimeVolumeIMTX
09:32 ET120111.93
09:34 ET30011.77
09:36 ET20011.71
09:38 ET20011.755
09:41 ET40611.76
09:45 ET200011.79
09:48 ET120011.795
09:50 ET40011.8
10:01 ET10011.87
10:06 ET30011.785
10:10 ET37211.8
10:17 ET105011.78
10:19 ET88111.8
10:21 ET20011.8
10:24 ET10011.8
10:30 ET30011.79
10:32 ET642011.795
10:33 ET110011.795
10:37 ET40011.795
10:39 ET99111.82
10:42 ET42211.79
10:44 ET175011.79
10:46 ET35811.79
10:48 ET136111.79
10:50 ET184911.77
10:51 ET171511.745
10:53 ET20011.74
10:55 ET10011.77
10:57 ET30011.77
11:00 ET20011.76
11:02 ET34311.78
11:04 ET50011.77
11:09 ET34811.8173
11:13 ET11511.79
11:15 ET10011.77
11:18 ET20011.785
11:20 ET125011.7919
11:22 ET10011.8
11:24 ET10011.79
11:26 ET20011.81
11:31 ET10011.82
11:33 ET20011.825
11:36 ET20011.8
11:38 ET50011.795
11:40 ET20011.8
11:42 ET42511.795
11:44 ET10011.81
12:02 ET10011.83
12:05 ET10011.82
12:07 ET10011.8
12:09 ET350511.85
12:12 ET20011.86
12:14 ET15711.85
12:18 ET40011.9
12:20 ET20011.9
12:23 ET115511.93
12:25 ET20011.91
12:27 ET10011.91
12:32 ET30011.92
12:34 ET20011.93
12:38 ET10011.92
12:45 ET93911.875
12:50 ET10011.875
12:54 ET42411.905
01:06 ET20011.87
01:10 ET40011.86
01:12 ET40011.86
01:15 ET10011.84
01:17 ET10011.81
01:19 ET50011.8
01:24 ET40011.82
01:26 ET40011.8
01:28 ET30011.795
01:30 ET30011.81
01:33 ET35011.8
01:35 ET20011.81
01:37 ET30011.8
01:42 ET20011.8
01:44 ET10011.82
01:46 ET30011.8
01:50 ET155011.82
01:51 ET220011.8125
01:53 ET30011.8
01:57 ET70011.85
02:02 ET30011.86
02:04 ET30011.83
02:06 ET10011.84
02:08 ET20011.82
02:09 ET10011.85
02:11 ET70011.815
02:13 ET10011.8001
02:15 ET20011.8
02:20 ET30511.82
02:22 ET40011.84
02:24 ET50011.85
02:27 ET20011.845
02:29 ET10011.855
02:31 ET50011.84
02:33 ET50011.87
02:36 ET10011.87
02:38 ET10011.86
02:40 ET40011.88
02:42 ET30011.85
02:45 ET20011.85
02:47 ET143011.89
02:49 ET49911.86
02:51 ET235811.88
02:54 ET30011.865
02:56 ET10011.875
02:58 ET30011.85
03:02 ET100011.84
03:03 ET40011.84
03:05 ET40911.84
03:07 ET20011.85
03:09 ET52511.845
03:12 ET10011.845
03:14 ET100011.84
03:16 ET10411.85
03:18 ET10011.845
03:20 ET30011.845
03:21 ET10011.845
03:23 ET30011.845
03:25 ET100011.86
03:27 ET30011.87
03:30 ET50011.86
03:32 ET72211.85
03:34 ET20011.85
03:36 ET65511.84
03:38 ET10011.85
03:39 ET40011.85
03:43 ET30011.84
03:45 ET50011.86
03:48 ET132411.84
03:50 ET87211.84
03:52 ET205411.86
03:54 ET198211.85
03:56 ET160011.84
03:57 ET156111.8
03:59 ET371911.82
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesIMTX
Immatics NV
1.2B
-11.3x
---
United StatesNRIX
Nurix Therapeutics Inc
1.2B
-7.7x
---
United StatesARQT
Arcutis Biotherapeutics Inc
1.1B
-3.2x
---
United StatesVIR
Vir Biotechnology Inc
1.3B
-2.3x
---
United StatesSLNCF
Silence Therapeutics PLC
930.9M
-16.7x
---
United StatesPRTA
Prothena Corporation PLC
1.1B
-6.1x
---
As of 2024-06-26

Company Information

Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.

Contact Information

Headquarters
Paul Ehrlich-Strasse 15TUEBINGEN, Germany 72076
Phone
---
Fax
---

Executives

Non-Executive Chairman of the Board
Peter Chambre
Chief Executive Officer, Executive Director
Harpreet Singh
Chief Financial Officer
Arnd Christ
Chief Operating Officer
Steffen Walter
General Counsel
Edward Sturchio

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.2B
Revenue (TTM)
$79.8M
Shares Outstanding
103.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.75
EPS
$-1.05
Book Value
$2.85
P/E Ratio
-11.3x
Price/Sales (TTM)
15.5
Price/Cash Flow (TTM)
---
Operating Margin
-119.20%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.